OBJECTIVE: To determine if suppressing Nogo-A, an axonal inhibitory protein, will promote functional recovery in a murine model of multiple sclerosis (MS). METHODS: A small interfering RNA was developed to specifically suppress Nogo-A (siRNA-NogoA). The siRNA-NogoA silencing effect was evaluated in vitro and in vivo via immunohistochemistry. The siRNA was administered intravenously in 2 models of experimental autoimmune encephalomyelitis (EAE). Axonal repair was measured by upregulation of GAP43. Enzyme-linked immunosorbent assay, flow cytometry, and (3)H-thymidine incorporation were used to determine immunological changes in myelin-specific T cells in mice with EAE. RESULTS: The siRNA-NogoA suppressed Nogo-A expression in vitro and in vivo. Systemic administration of siRNA-NogoA ameliorated EAE and promoted axonal repair, as demonstrated by enhanced GAP43+ axons in the lesions. Myelin-specific T-cell proliferation and cytokine production were unchanged in the siRNA-NogoA-treated mice. INTERPRETATION: Silencing Nogo-A in EAE promotes functional recovery. The therapeutic benefit appears to be mediated by axonal growth and repair, and is not attributable to changes in the encephalitogenic capacity of the myelin-specific T cells. Silencing Nogo-A may be a therapeutic option for MS patients to prevent permanent functional deficits caused by immune-mediated axonal damage.
OBJECTIVE: To determine if suppressing Nogo-A, an axonal inhibitory protein, will promote functional recovery in a murine model of multiple sclerosis (MS). METHODS: A small interfering RNA was developed to specifically suppress Nogo-A (siRNA-NogoA). The siRNA-NogoA silencing effect was evaluated in vitro and in vivo via immunohistochemistry. The siRNA was administered intravenously in 2 models of experimental autoimmune encephalomyelitis (EAE). Axonal repair was measured by upregulation of GAP43. Enzyme-linked immunosorbent assay, flow cytometry, and (3)H-thymidine incorporation were used to determine immunological changes in myelin-specific T cells in mice with EAE. RESULTS: The siRNA-NogoA suppressed Nogo-A expression in vitro and in vivo. Systemic administration of siRNA-NogoA ameliorated EAE and promoted axonal repair, as demonstrated by enhanced GAP43+ axons in the lesions. Myelin-specific T-cell proliferation and cytokine production were unchanged in the siRNA-NogoA-treated mice. INTERPRETATION: Silencing Nogo-A in EAE promotes functional recovery. The therapeutic benefit appears to be mediated by axonal growth and repair, and is not attributable to changes in the encephalitogenic capacity of the myelin-specific T cells. Silencing Nogo-A may be a therapeutic option for MSpatients to prevent permanent functional deficits caused by immune-mediated axonal damage.
Authors: R Prinjha; S E Moore; M Vinson; S Blake; R Morrow; G Christie; D Michalovich; D L Simmons; F S Walsh Journal: Nature Date: 2000-01-27 Impact factor: 49.962
Authors: Xingxing Wang; Soo-Jin Chun; Helen Treloar; Timothy Vartanian; Charles A Greer; Stephen M Strittmatter Journal: J Neurosci Date: 2002-07-01 Impact factor: 6.167
Authors: Kevin C Wang; Vuk Koprivica; Jieun A Kim; Rajeev Sivasankaran; Yong Guo; Rachel L Neve; Zhigang He Journal: Nature Date: 2002-06-16 Impact factor: 49.962
Authors: Yuhong Yang; Jeffrey Weiner; Yue Liu; Alan J Smith; David J Huss; Ryan Winger; Haiyan Peng; Petra D Cravens; Michael K Racke; Amy E Lovett-Racke Journal: J Exp Med Date: 2009-06-22 Impact factor: 14.307
Authors: Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab Journal: CNS Drugs Date: 2017-03 Impact factor: 5.749
Authors: Mary E Severin; Priscilla W Lee; Yue Liu; Amanda J Selhorst; Matthew G Gormley; Wei Pei; Yuhong Yang; Mireia Guerau-de-Arellano; Michael K Racke; Amy E Lovett-Racke Journal: Brain Date: 2016-04-28 Impact factor: 13.501